Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Jun 11;1910(1):178. doi: 10.1007/s40278-022-17013-4

Dexamethasone

Lack of efficacy and off-label use: case report

PMCID: PMC9184398

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 74-year-old man exhibited lack of efficacy with off-label use of dexamethasone in SARS-CoV-2 infection [route and dosage not stated].

The man presented with renal insufficiency post SARS-CoV-2 infection. He was diagnosed with SARS-CoV-2 infection in 2020. His vaccination history was negative for SARS-CoV-2. He developed severe pneumonia, while on off label treatment with dexamethasone (lack of efficacy), and was managed with extracorporeal membrane oxygenation and artificial respiration. He was hospitalised for 5 months. Prior to SARS-CoV-2 infection, he was never suspected to have nephritis. During the treatment of SARS-CoV-2 infection, his renal function altered and abnormalities were noted in urinalysis. Therefore, he was referred after 1 month from his discharge. On admission, apart from pitting oedema in his leg, he had no other abnormalities. Laboratory investigations revealed the following: creatinine 3.09 mg/dL, IgA 461 mg/dl, proteinase-3 antineutrophil cytoplasmic antibodies (ANCA) <0.5 IU/mL, serum anti-glomerular basement membrane antibody <0.2 IU/mL. Urinalysis revealed proteinuria and microscopic haematuria. Kidney biopsy showed moderate mesangial cell proliferation and cellular crescents in 4 of 20 glomeruli. The MEST-C classification of the kidney biopsy was M1E1S1T1C2. Immunofluorescence test revealed deposition of IgA and C3 in the mesangial regions. Based on the investigations, a diagnosis of IgA nephropathy was considered. He underwent tonsillectomy and steroid pulse therapy. After 35 days of treatment, his creatinine levels and proteinuria improved.

Reference

  1. Yonishi H, et al. New-onset immunoglobulin-A nephropathy post severe acute respiratory syndrome-coronavirus-2 infection indicates rapidly progressive glomerulonephritis. Nephrology 27: 542-543, No. 6, Jun 2022. Available from: URL: 10.1111/nep.14003 [DOI] [PMC free article] [PubMed]

Articles from Reactions Weekly are provided here courtesy of Nature Publishing Group

RESOURCES